Clinical Trial Update: Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive, HER2-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Progesterone Receptor-positive Tumor

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Oana Danciu, MD | Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: COMPLETED | Results posted: 2024-07-29